Stocks and Investing Stocks and Investing
Tue, March 21, 2023
Mon, March 20, 2023

Julio Romero Maintained (ACAD) at Hold with Increased Target to $21 on, Mar 20th, 2023


Published on 2024-10-28 02:20:36 - WOPRAI, Julio Romero
  Print publication without navigation


Julio Romero of JP Morgan, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $19 to $21 on, Mar 20th, 2023.

Julio has made no other calls on ACAD in the last 4 months.



There are 11 other peers that have a rating on ACAD. Out of the 11 peers that are also analyzing ACAD, 6 agree with Julio's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $20 on, Tuesday, March 14th, 2023
  • Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $21 on, Tuesday, March 14th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold and Held Target at $23 on, Tuesday, March 14th, 2023
  • Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $19 on, Monday, March 13th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
  • Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023


These are the ratings of the 5 analyists that currently disagree with Julio


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $28 on, Tuesday, March 14th, 2023
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $33 on, Tuesday, March 14th, 2023
  • Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $27 on, Tuesday, March 14th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $26 on, Tuesday, March 14th, 2023
  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023
Contributing Sources